---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-034019"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2024-08-27T23:59:59+00:00"
generated_at: "2026-05-31T07:20:11.167148+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Elite Pharmaceuticals launches generic methotrexate sodium 2.5 mg tablets

## Summary
- Product launched for ALL, mycosis fungoides, non-Hodgkin's lymphoma, rheumatoid arthritis, severe psoriasis, pJIA.
- Total US market for methotrexate sodium 2.5 mg tablets was ~$63M (12 months ended May 2024, IQVIA).
- Marketed under Elite Laboratories, Inc. label; DEA/cGMP facility in Northvale, NJ.
- Elite (OTCQB: ELTP) develops and manufactures niche generic products.

## SEC filing metadata
- accession: 0001493152-24-034019
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2024-08-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315224034019/0001493152-24-034019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315224034019/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-034019
- JSON: https://secwatch.observer/filing/0001493152-24-034019.json
- Plain text: https://secwatch.observer/filing/0001493152-24-034019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.